Papillary Thyroid Carcinoma Developments After Radioactive Iodine Treatment for Toxic Adenoma: A Case Report

Cevdet Duran, Mustafa Cayci, Orkide Kutlu, Baris Sevinc, Omer Karahan, Samil Ecirli, Ceyhan Ugurluoglu


Radioiodine is an important radiopharmaceutical agent in nuclear medicine practice for the treatment of hyperthyroidism and differenciated thyroid cancer. One of the long term side effects of ionising radiation is the possibility of radiation induced malignancy. There are limited reports about malignancy after 131I therapy for thyrotoxicosis. In this report, a case with papillary thyroid cancer after radioactive iodine (RAI) therapy for toxic thyroid nodule is presented. In this case, fine needle aspiration biopsy(FNAB) had not been done before RAI therapy and papillary carcinoma was detected four years later than the 444 MBq RAI therapy. The patient underwent bilateral total thyroidectomy and central neck dissection. After the surgery, the patient underwent 5550 MBq RAI for ablation. Summary, differentiated thyroid cancer can be found incidentally in toxic nodule or can be developed as a consequence of radioiodine therapy. FNAB must be performed for all the patients with hot or cold thyroid nodules before RAI therapy and all the patients taking RAI theraphy should be closely followed in terms of nodule growing and cancer development.

J Med Cases. 2013;4(10):686-688


Thyroid cancer; 131I therapy; Toxic adenoma

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.